Exelixis, Inc. Stock price

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
23.17 USD +0.83% Intraday chart for Exelixis, Inc. +3.16% -3.42%
Sales 2024 * 1.9B Sales 2025 * 2.07B Capitalization 7.03B
Net income 2024 * 377M Net income 2025 * 446M EV / Sales 2024 * 3.1 x
Net cash position 2024 * 1.12B Net cash position 2025 * 1.65B EV / Sales 2025 * 2.59 x
P/E ratio 2024 *
18.8 x
P/E ratio 2025 *
15.7 x
Employees 1,310
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.85%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Exelixis, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Transcript : Exelixis, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 09:20 AM
Transcript : Exelixis, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing MT
Transcript : Exelixis, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-13-2024 12:40 PM
Transcript : Exelixis, Inc. Presents at Guggenheim Healthcare Talks| 6th Annual Biotechnology Conference, Feb-08-2024 09:00 AM
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating MT
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set MT
Transcript : Exelixis, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024 CI
Earnings Flash (EXEL) EXELIXIS Reports Q4 Revenue $480M, vs. Street Est of $477.9M MT
Earnings Flash (EXEL) EXELIXIS Posts Q4 EPS $0.33, vs. Street Est of $0.31 MT
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Barclays Adjusts Price Target on Exelixis to $25 From $24, Keeps Overweight Rating MT
More news
1 day+0.83%
1 week+3.16%
Current month+5.80%
1 month+13.13%
3 months-0.73%
6 months+8.52%
Current year-3.42%
More quotes
1 week
22.40
Extreme 22.4
23.42
1 month
20.43
Extreme 20.43
23.42
Current year
19.20
Extreme 19.2
24.34
1 year
17.90
Extreme 17.9
24.34
3 years
14.87
Extreme 14.87
25.77
5 years
13.67
Extreme 13.67
27.80
10 years
1.26
Extreme 1.26
32.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 00-01-31
Director of Finance/CFO 56 15-07-14
Chief Tech/Sci/R&D Officer 57 23-08-22
Members of the board TitleAgeSince
Director/Board Member 68 04-12-31
Director/Board Member 68 04-01-31
Director/Board Member 79 04-07-31
More insiders
Date Price Change Volume
24-03-18 23.17 +0.83% 2,385,578
24-03-15 22.98 +1.64% 4,872,379
24-03-14 22.61 -1.99% 2,471,694
24-03-13 23.07 +1.67% 2,642,660
24-03-12 22.69 +1.02% 2,492,894

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
23.17 USD
Average target price
26.63 USD
Spread / Average Target
+14.94%
Consensus
  1. Stock
  2. Equities
  3. Stock Exelixis, Inc. - Nasdaq